QIAGEN-JPM-202401.pdf

1、Leveraging top sample prep position to expand leadership in Life Sciences and Molecular Diagnostics42ndAnnual J.P.Morgan Healthcare ConferenceThierry BernardChief Executive OfficerRachel HallCo-founder of GNOMIXAdelaide,AustraliaDisclaimerSafe Harbor Statement:This presentation contains both histori

2、cal and forward-looking statements.All statements other than statements of historical fact are,or may bedeemed to be forward looking statements within the meaning of Section 27A of the U.S.Securities Act of 1933,as amended,and Section 21E of the U.S.SecuritiesExchange Act of 1934,as amended.These st

3、atements are based on current expectations of future events.If underlying assumptions prove inaccurate or unknown risks oruncertainties materialize,actual results could vary materially from our own expectations and projections.Some of the factors that could cause actual results to differinclude,but

4、are not limited,to the following:general industry conditions and competition;risks associated with managing growth and international operations(including theeffects of currency fluctuations,regulatory processes and dependence on logistics),variability of operating results and allocations between cus

5、tomer classes,and thecommercial development of markets for our products to customers in academia,pharma,applied testing and molecular diagnostics;changing relationships with customers,suppliers and strategic partners;competition;rapid or unexpected changes in technologies;fluctuations in demand for

6、QIAGENs products(including factors such asgeneral economic conditions,the level and timing of customers funding,budgets and other factors);our ability to obtain regulatory approval of our products;technologicaladvances of our competitors and related legal disputes;difficulties in successfully adapti